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Luciferase–Rose Bengal conjugates for singlet
oxygen generation by bioluminescence resonance
energy transfer†
Seonghoon Kim, ab HyeongChan Jo,b Mijeong Jeon, b Myung-Gyu Choi, c
Sei Kwang Hahn d and Seok-Hyun Yun *ab
Conjugates of Rose Bengal and Renilla luciferase generated singlet
oxygen upon binding with coelenterazine via bioluminescence
resonance energy transfer (BRET). Since the applications of conventional
PDT have been limited to superficial lesions due to the limited
light penetration in tissue, BRET activated PDT which does not
require external light illumination may overcome the limitations of
conventional PDT.
Photodynamic therapy (PDT) is used clinically to treat dermatologic
lesions, retinal diseases, and epithelial tumors.1,2 PDT employs
photosensitizer (PS) molecules and uses light to activate drugs to
generate reactive oxygen species (ROS), such as singlet oxygen,
and free radicals. These photochemical products can kill target
cells and destruct tissues. This toxicity mechanism is diﬀerent from
the cytotoxicity mechanisms of chemotherapy, radiation therapy
and immunotherapy. The diﬀerence makes PDT an attractive
option for stand-alone or combinatorial therapy. Another distinct
aspect of PDT comes from the light-induced activation of photo-
sensitizers. This provides an advantage of spatial and temporal
controllability of drug activation. However, the need for light also
limits the applications of PDT, because of the light’s shallow
penetration depth in tissues. To date, clinical PDT has been adopted
to treat diseases in the skin and retina, which physicians can readily
approach with a light source, or in epithelial layers of endoscopically
accessible sites such as gastrointestinal tracts. To enhance the
therapeutic depth of PDT, considerable eﬀorts have been made in
developing PS3 molecules with action spectra in the near-infrared
(NIR) range and up-conversion nanoparticles4 that absorb NIR
photons and deliver energy to conventional PS drugs. Yet, the
limited optical penetration depth (o5 mm) even in the NIR
range leaves many diseases out of reach.
To solve this problem, researchers have sought new methods
capable of remotely activating PS agents in deep tissues. One such
approach is to use Cherenkov radiation produced by beta particles
during radioactive decay.5 However, the potential toxicity of radio-
active isotopes and inorganic photosensitive nanoparticles, such
as TiO2, needs to be addressed for clinical translation.
6 Another
approach is to use Fo¨rster resonance energy transfer from
chemiluminescent or bioluminescent molecules. Yuan et al.
demonstrated antimicrobial PDT by employing luminol and
electrostatically-bound cationic oligo(p-phenylene vinylene).7
Hsu et al. demonstrated cancer therapy by using self-illuminating
quantum dots conjugated with mutant Renilla luciferases.8 Kim
et al. extended this approach and demonstrated local therapy of
cancer cells in draining lymph nodes in mice.9 While these
experiments support the feasibility of remotely activated PDT,
the long-term toxicity of luminol and quantum dots raise concern
about their potential for clinical translation. Furthermore, because
donors (luciferases) and acceptors (PSs) are administered separately,
bioluminescence resonance energy transfer (BRET) occurs only
when they are located close to each other within 5–10 nm. Chemical
conjugation of bioluminescent enzymes and PS drugs could solve
this problem, but such BRET pairs have not been demonstrated.
Here, we report the conjugation of a luciferase and a PS, for
the first time to our knowledge. In this work, we have used
mutant Renilla luciferases 8.6 (RLuc8.6)10 and Rose Bengal (RB)
dyes to form BRET pairs (Fig. S1, ESI†), where the emission
peak of RLuc8.6 at 535 nm is well matched with an RB’s
absorption peak at 550 nm. RB is an eﬃcient PS with a high
quantum eﬃciency of 0.7–0.8 (measured in aqueous media) in
the generation of singlet oxygen.11 We have investigated the
efficiency of singlet oxygen generation and the ROS-induced
cytotoxicity of the luciferase–RB conjugates for BRET-induced
PDT in direct comparison with laser-induced activation used in
conventional PDT.
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Our initial scheme for conjugating RLuc8.6 and RB via a
short linker retained bioluminescence (BL) capability but failed
to achieve eﬃcient BRET to RB (Fig. S2, ESI†) presumably due
to the quenching of the RB. To solve this problem, we used
bovine serum albumin (BSA) as a central piece to which
RLuc8.6 and RB were conjugated. The rationales for this design
were to provide space between RB and RLuc8.6 to evade
quenching and enhance the BRET eﬃciency by attaching multiple
RLuc8.6 molecules in each complex. When the mixing ratio of RB
to BSA was 5 : 1, the highest FL intensity was measured from
RB–BSA conjugates (Fig. S3a, ESI†). The actual conjugation ratio
was estimated to be 2.2 : 1 by comparing the absorbance of
purified RB–BSA conjugates to the absorbance of unpurified
simple mixtures of RB–NHS and BSA (Fig. S3b, ESI†). RLuc8.6
was linked to the RB–BSA conjugate by Cu-free click reaction to
form an RB–BSA–PEG4–RLuc8.6 conjugate, hereinafter called LucRB
(Scheme 1). A polyacrylamide gel electrophoresis of LucRB purified
with a 100 kDa filter showed bands near 140, 180, 210 and 250 kDa,
respectively, corresponding to 2, 3, 4 and 5 RLuc8.6 molecules per
construct (Fig. S3c, ESI†). The LucRB conjugates with heterogeneous
molecular weights were used in the experiments without further
purification. The hydrodynamic size and zeta potential of LucRB
were measured to be 11 nm and 6.6 mV, respectively.
While RLuc8.6 is colorless, LucRB solution has a pink color
owing to RB (Fig. 1a). When CTZ was administered, LucRB
produced significantly lower BL emission intensity compared
to RLuc8.6 solution. This is because of the BRET to RB, and RB
has a low fluorescence quantum yield (QY) of B5% compared
to RLuc8.6’s high BL QY of B50% (Fig. 1a). To confirm the
enzymatic activity of RLuc8.6 in LucRB, we measured the time-
lapse curves of BL intensity using a large-area detector (Fig. 1b,
inset). We found that the total BL energy integrated over the
entire emission time was linearly proportional to the amount of
CTZ (up to 10 mg) but independent of sample concentration.
The exponential decay rates of BL emission from free RLuc8.6
measured as a function of concentration followed the Michaelis-
Mentens kinetic model of the substrate–enzyme reaction (Fig. 1b).
The BL decay rate of LucRB at a concentration of 0.4 mM was
equivalent to the BL decay rate of RLuc8.6 solution at a concen-
tration of 1.51 mM. This means that the average number of RLuc8.6
in a single LucRB molecule was about 3.8.
RLuc8.6 has a broad BL spectrum that overlaps well with the
absorption spectrumof RB (Fig. 1c). By comparison, the BL spectrum
of LucRB showed an additional shoulder around 580 nm (Fig. 1d).
The diﬀerence of the LucRB and RLuc8.6 spectra corresponded to
the FL emission spectrum of RB (Fig. 1c and d). The BRET ratio,
defined as the FL emission energy from the acceptor (RB) to the BL
emission energy of the donor (RLuc8.6), ismeasured to be 7.5%. The
relative QYs of free RB (0.05) and LucRB (0.02) were estimated by
comparison with the FL intensity of Rhodamine 6G (QY, 0.95) upon
532 nm excitation in PBS solution. We estimated energy transfer
eﬃciency by comparison with the total BL energy from RLuc8.6
(50 mJ) and transferred energy to RB (23.2 mJ) calculated by
dividing RB fluorescence energy (B–A, 0.44 mJ) of LucRB by the
LucRB’s QY. The calculated BRET efficiency is 46.4% (= 23.2/50 mJ).
In summary, 46.4% of the total optical energy is transferred to RB,
and 2% of the transferred energy is emitted as FL, while the rest
contributes to the generation of singlet oxygen and ROS.
To quantify singlet oxygens generated by the excitation of
LucRB, we used a Singlet Oxygen Sensor Green (SOSG) dye whose
FL emission is increased by singlet oxygen.12,13 We found that the
Scheme 1 Schematics of the synthesis of a LucRB conjugate and its action
for the generation of reactive oxygen species (ROS) via bioluminescence-
resonance energy transfer (BRET). RB, Rose Bengal; BSA, bovine serum
albumin; CTZ, coelenterazine; CTM, coelecteramide; BL, bioluminescence;
FL, fluorescence.
Fig. 1 Optical properties of LucRB. (a) Photographs of RLuc8.6 (i, ii) and
LucRB (iii, iv) solutions in cuvettes. Left (i, iii): under room light, right (ii, iv):
BL in the dark. For 10 mg of CTZ each, the total BL energy emitted from
RLuc8.6 (1.5 mM) and LucRB solutions (0.4 mM; same number of RLuc8.6)
was estimated to be 50 mJ and 5.8 mJ, respectively. (b) BL emission decay
rates and total fluence of LucRB and RLuc8.6 as a function of concentration
in PBS buﬀer (pH 7.4). (c) Normalized absorption (magenta), FL (orange) and
BL (cyan) spectra of RB and RLuc8.6. (d) Normalized BL of LucRB (B) and
Luc8.6 (A), and the diﬀerence (B–A). The inset shows that the difference
(magenta dotted line) coincides with the FL spectrum (orange) of LucRB.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
M
ar
ch
 2
01
7.
 D
ow
nl
oa
de
d 
on
 6
/1
9/
20
19
 8
:2
6:
37
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2017 Chem. Commun., 2017, 53, 4569--4572 | 4571
FL intensity of SOSG was aﬀected when directly exposed to CTZ,
but this interference was suppressed by adding BSA proteins to
SOSG-containing solution before adding CTZ and LucRB. The
premixing with BSA stabilized SOSG so that the FL output was
invariant by CTZ up to 100 mg in 2 ml (118 mM) in the absence of
LucRB (Fig. 2a, control). By contrast, in the presence of 2 nmol
(1 mM) of LucRB, the FL intensity of SOSG increased linearly with
increase in the amount of CTZ up to 50 mg (60 mM) until it
saturated fully above 65 mg (77 mM) (Fig. 2a). The saturation of
SOSG signals at high CTZ concentrations may be in part due to
the degradation of LucRB molecules by the generated ROS
through repeated enzymatic actions with the substrates. Laser-
excited LucRB (532 nm, 1 mW cm2) without CTZ exhibited a
similar linear growth trend as a function of irradiation time
(Fig. 2b). This result indicates that for LucRB (1 mM) CTZ (50 mg)
can generate as much singlet oxygen as the laser excitation at a
fluence of B360 mJ cm2 (6 min at 1 mW cm2).
To test LucRB in vitro, we used CT26 cells (murine colon
carcinoma cell line) in monolayer culture. Unfortunately, bare
LucRB conjugates have a low binding aﬃnity to the cell membrane
and thus low internalization eﬃciency into the cytoplasm. This
resulted in nearly no cytotoxicity in both BRET- and laser-excited
PDT (532 nm, 1mW cm2). To solve this problem, we coupled cell-
penetrating peptides (CPP) to LucRB non-covalently. The CPP
coupling considerably enhanced the delivery eﬃciency of LucRB
into cells. To quantify the intracellular concentration of LucRB, we
measured optical absorption at 550 nm through monolayer cells
incubated with 100 mM of CPP-coupled LucRB solution. The
measured absorption value (1.6%) was the same as the absorption
by monolayer cells incubated with bare-RB solution at a
concentration of 12 mM (Fig. 3a). Furthermore, under a laser-
excited confocal fluorescence microscope, the intensity of
intracellular RB fluorescence from these cells was equivalent
to the fluorescence intensity from a bare-RB solution at a
concentration of 2.4 mM. These data indicate that the intracellular
concentration of RB is B5 times lower than the extracellular
concentration in the cell medium and that, considering that each
LucRB contains average 2.2 RBmolecules, the intracellular delivery
eﬃciency of LucRB was 1.1%.
MTT assays showed no significant cytotoxicity of CTZ at
concentrations up to 10 mg in 100 ml of culture medium (232 mM)
(Fig. 3b(i)). For CT26 cells incubated at 100 mM LucRB,
administration of 10 mg CTZ resulted in cell death in 40% of
the cell population (Fig. 3b(ii)). For cells incubated with a ROS
scavenger, NaN3, prior to CTZ administration, cell death was
negligible (Fig. 3b(iii)), which confirms that the cytotoxicity
mechanism is mediated by BRET-induced ROS. For the same
LucRB concentration (100 mM) we performed laser-excited PDT
at an optical fluence of 600 mJ cm2 (532 nm, 10 mW cm2,
1 min) and achieved a similar level (40%) of cell death (Fig. 3c(i)).
Laser-induced PDT was performed on cells incubated with bare
RB molecules at varying concentrations. The cell death ratio by
laser-excited RB at 10 mM (equivalent intracellular RB concentration
to 100 mM LucRB) was about 40% (Fig. 3c(ii)), again the same as
above. Therefore, these results further support that the cytotoxicity
mechanism of LucRB is due to BRET-induced ROS generation.With
higher RB concentrations of 30 and 50 mM, the cell death ratio
increased to 65 and 75%, respectively. This result is encouraging as
it indicates that higher intracellular concentrations of LucRB might
produce stronger cytotoxicity.
We performed confocal fluorescence imaging of cells using
20,70-dichlorofluorescein diacetate (DCFDA), an ROS indicator.
CT26 cells incubated with LucRB show red FL from RB but very
low green FL from DCF, indicating low intracellular ROS levels
(Fig. 4a). As a positive control, cells incubated with hydrogen
peroxide showed strong green FL from oxidized DCF (Fig. 4b). As
another positive control, cells incubated with bare RB (10 mM)
and treated with laser light (532 nm, 10 mW cm2, 1 min)
Fig. 2 Measurement of ROS generation. (a) FL signal of SOSG increased
linearly when CTZ up to 50 mg in 2 ml (47 mM) was added to LucRB (1 mM)
solution until it saturated beyond 50 mg, whereas the SOSG signal
was invariant in the absence of LucRB (control). (b) Comparison to laser-
induced excitation. The SOSG signal from LucRB that was excited by laser
light (532 nm, 1 mW cm2) increased linearly with increasing irradiation
time. An optical energy ofB360 mJ (green arrow) produced an equivalent
amount of ROS to the maximum produced by 50 mg of CTZ in (a).
Fig. 3 In vitro cytotoxicity assay. (a) Estimated intracellular concentration of
LucRB from light absorption by RB ([int. RB]/2.2 = [LucRB], LucRB =B5.5 mM).
(b) MTT assay of BRET-PDT (LucRB: 100 mM, CTZ: 118 mM (10 mg/200 ml),
NaN3: 1 mM). (c) MTT assay of conventional laser-induced PDT.
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generated both red and green FL, confirming ROS generation
(Fig. 4c). Cells incubated with LucRB and treated with either laser
illumination (10 mW cm2, 1 min) or CTZ administration (10 mg)
exhibited green FL fromDCF in 50–70% of the cells (Fig. 4d and e).
To quantify DCF FL, flow cytometry was performed subsequently
(Fig. 4f–i). Cells incubated with CTZ alone (Fig. 4g) or LucRB prior
to CTZ (Fig. 4i) produced slightly higher FL compared to cells
without DCFDA (Fig. 4f), but much lower than positive controls
incubated with hydrogen peroxide (Fig. 4h). Cells treated with
LucRB and CTZ showed a significant increase of DCF signals
proportional to the amount of CTZ (5 and 10 mg) (Fig. 4i).
The optimization of the conjugation ratio and inter-molecular
separation resulted in nearly 50% eﬃciency in energy transfer
from the bioluminescent enzyme–substrate complex to the
conjugated PS. The total amount of BL energy produced from
10 mg of CTZ (that is, 1.4  1016 molecules) and an excessive
amount of free RLuc8 was measured to beB50 mJ. 10 mg of CTZ
in 100 ml of solution in the cuvettes (Fig. 3) and cytoplasm
(Fig. 4) produced the same amount of ROS as that produced
from LucRB solution after laser excitation at a dose ofB600 mJ
(10 mW for 1 min). The difference between 600 mJ and 50 mJ may
be interpreted as the higher ‘‘photon’’ efficiency of the near-field
BRET-induced activation compared to the far-field laser excitation.
Given that RB has an extinction coefficient of 90000 M1 cm1 at
550 nm and an absorption cross-section of 2.4  1016 cm2, a
monolayer of cells (5 mm thick) with 10 mM RB in the cytoplasm
would absorb only 0.1% of the topically illuminated light. This
accounts for a three orders of magnitude difference in efficiency
compared to BRET-induced activation where most of the virtual-
photon energy (B50%) is transferred to RB.
The mechanism of PDT based on ROS generation from LucRB
is distinctively diﬀerent from chemotherapy and radiation therapy.
No cross-resistance between BRET-induced PDT and chemotherapy
has been known.14 Conventional PDT has been shown to be
eﬀective against radio-resistant and chemo-resistant cells15,16 and,
also, may sensitize resistant cells to chemotherapy.17 Therefore,
BRET-PDT has potential for combination therapy with chemo- and
radio-therapy. Unlike conventional chemo agents, LucRB agents
are non-toxic on their own until activated by the administration of
CTZ. This temporal switch allows BRET PDT to be performed at
optimal timing when the most preferred bio-distribution of the
drug and maximal therapeutic outcome can be achieved.
The relatively low intracellular uptake eﬃciency of LucRB
limited the amount of cytotoxicity. Other known delivery methods,
such as liposomal delivery,18 may increase the intracellular uptake
eﬃciency and thus improve the therapeutic potential. Conjugation
of LucRB to antibodies against specific cell-surface biomarkers
may enhance targeting and cytotoxicity to tumor cells.3 Finally,
other possible combinations of diﬀerent types of luciferases,
photosensitizers, and substrates appear to have potential and
are worth investigation for BRET-PDT.
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Fig. 4 Measurement of oxidative stress in CT26 cells. (a–e) Intracellular
ROS generation by BRET-PDT (red: RB or LucRB, green: DCFDA). (f–i) Flow
cytometry analysis of DCFDA FL.
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